NCT02754180

Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 110 (estimated)
• Sponsor: Peking Union Medical College Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes after curative resection.

Detailed description

Adjuvant Gemcitabine Versus Gemcitabine With TS-1 based Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes after curative resection: a randomized phase II study.

Conditions

• Pancreatic Neoplasms

Interventions

Type	Name	Description
DRUG	Gemcitabine	gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles
RADIATION	TS-1 with radiation	gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles. Followed by TS-1 based chemoradiation. TS-1 40mg/m2 bid, 5 days/week, with radiation.

Timeline

• Start date: 2016-03-01
• Primary completion: 2019-03-01
• Completion: 2021-03-01
• First posted: 2016-04-28
• Last updated: 2016-04-28

Locations

1 site across 1 country: China